Sexual function 1-year after allogeneic hematopoietic stem cell transplantation.

Area of Science:

• Oncology
• Hematology
• Reproductive Medicine

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving procedure but carries significant short and long-term toxicities.
• Sexual dysfunction is a recognized but often under-addressed toxicity following HSCT.
• The impact of HSCT on sexual functioning, body image, anxiety, and depression requires further prospective investigation.

Purpose of the Study:

• To prospectively evaluate the prevalence and impact of sexual dysfunction one year after allogeneic HSCT.
• To determine associations between sexual dysfunction and psychological factors including body image, anxiety, and depression post-HSCT.
• To assess the influence of chronic graft-versus-host disease (GVHD) on sexual function after HSCT.

Main Methods:

• A controlled prospective cohort study involving 124 patients before HSCT and 63 patients one year after HSCT.
• Utilized validated questionnaires: Sexual Functioning Questionnaire, Body Image Scale, and Hospital Anxiety and Depression Scale.
• Collected descriptive data and assessed sexual function, body image, anxiety, and depression at two time points.

Main Results:

• A significant decline in overall sexual function was observed in both men (P<0.001) and women (P=0.010) one year post-HSCT.
• 47% of men and 60% of women reported at least one physical sexual problem one year after HSCT.
• Women with chronic GVHD reported significantly lower sexual function compared to those without (P=0.008).

Conclusions:

• Sexual dysfunction is a prevalent and persistent issue for both men and women one year following allogeneic HSCT.
• Sexual dysfunction is associated with negative impacts on body image, anxiety, and depression.
• Routine screening and management of sexual dysfunction are crucial components of post-HSCT care.